ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy

Ozdemir, Ozer; Ozdemir, Pelin; Veral, Ali; Uluer, Hatice; Ozhan, Mustafa Hikmet

추천

검색

자료유형: 학술저널

저자정보: Ozdemir, Ozer (Department of Chest Diseases, Ege University Faculty of Medicine) Ozdemir, Pelin (Department of Chest Diseases, Ege University Faculty of Medicine) Veral, Ali (Department of Pathology, Ege University Faculty of Medicine) Uluer, Hatice (Department of Biostatistics, Ege University Faculty of Medicine) Ozhan, Mustafa Hikmet (Department of Chest Diseases, Ege University Faculty of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제8호

발행연도: 2013.1

수록면: 4,679 - 4,683 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients. Materials and Methods: Pretreatment tumor biopsy samples of 83 stage 3B and 4 non-small cell lung cancer patients treated with platinum based chemotherapy were retrospectively analyzed for immunohistochemical ERCC1 expression. None of the patients received curative surgery or radiotherapy. Results: By calculating H- scores regarding the extent and intensity of immunohistochemical staining of tumor biopsy samples, ERCC1 expression was found to be positive in 50 patients (60.2%). ERCC1 positive and negative groups had no statistically significant differences regarding treatment response, progression free survival and overall survival (respectively p=0.161; p=0.412; p=0.823). Conclusions: In our study we found no association between ERCC1 expression and survival or treatment response. The study has some limitations, such as small sample size and retrospective analysis method. There is need of more knowledge for use of ERCC1 guided chemotherapy regimens in advanced stage NSCLC.

#Non-small cell lung cancer #lung cancer chemotherapy #ERCC1 #molecular markers

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요